call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Global Devices For Inhaled Medications Market
Inquire Before Buying Request for Sample

Global Devices For Inhaled Medications Market

Home Medical Devices Global Devices For Inhaled Medications Market

Global Devices for Inhaled Medications Market, By Application (Commercial & Household), By Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2020-2026

  • Published Date: January 2021
  • Report ID: BWC202
  • Available Format: PDF
  • Page: 178

Report Overview

The global Devices for Inhaled Medications market is expected to reach USD  million by 2026, growing at a CAGR of % during the forecast period (2020-2026).

Global Devices for Inhaled Medications Market Size – Industry Trends & Forecast Report 2026

The global Devices for Inhaled Medications market is expected to reach USD  million by 2026, growing at a CAGR of % during the forecast period (2020-2026). Devices such as nebulizers have been used in hospitals to deliver drugs more effectively with minimal side effects on patients; inhalers are widely used due to their integration with smart technology; the number of smokers is on the rise and air pollution is rapid On the rise, the lung disease epidemic is the driving force behind the growth of the global inhaler market. The use of smart technology in the production of smart inhalers paves the way for future market growth, and the growth trend of micro-devices contributes to the growth of the market.

Source: BlueWeave Consulting

 

Global Devices for Inhaled Medications Market Overview:

Lung-based drugs are usually provided to prevent or alleviate asthma attacks and other respiratory diseases. Inhaled drugs or directly inhaled drugs are an important part of the treatment of chronic lung diseases. Various drugs are available in inhaled form. After inhalation, the drug will quickly reach the respiratory tract and be less absorbed into the blood. Many devices deliver drugs directly to the airway. Metered-dose inhalers (MDI), dry powder inhalers, nebulizers, and soft mist inhalers are currently available for a variety of drugs. Combinations of inhaled drugs can be used for many chronic lung diseases, including asthma and COPD. 

 

Global Devices for Inhaled Medications Market Forecast and Trends

 

Growth Drivers

 

Rise in prevalence of respiratory diseases

The prevalence of respiratory illnesses (COPD, asthma, emphysema, etc.) is increasing, the demand for first aid drugs during sudden asthma attacks is increasing, and the demand for short-term effective drugs is rapidly increasing. Also, manufacturers will focus on developing advanced portable inhalers, and government awareness programs for COPD and asthma symptoms are expected to drive market growth.

 

Increasing geriatric population 

According to the US Census Bureau, the 2010 census found that there were 40.3 million US residents aged 65 and over, and as of July 1, 2019, there were more than 54 million. According to the United Nations, between 2015 and 2030, that number is estimated to increase by 56% of people aged 60 and over worldwide (from 901 million to more than 1.4 billion). Hence, this is because asthma is a widespread disease among people over 65. Asthma in older people can cause serious health problems if not properly treated. Senior population growth is expected to drive market growth over the forecast period. However, inadequate cost recovery policies and strict regulatory requirements are expected to hamper the growth of asthma and COPD market.

 

Restraints

 

High cost of some inhalation devices and treatment.

Over the past few decades, the prevalence and incidence of asthma have increased worldwide due to exposure to a variety of risk factors, mostly related to the environment and lifestyle, as well as genetic background. Also, there are significant differences in cost estimates between studies in the same country. For example, US estimates of the per capita cost of asthma differ by up to five times. Despite different conditions and numbers, many studies indicate that the indirect costs of asthma are at least as high as the direct costs.

 

Impact of COVID-19 in the industry

 

In 2020, patients with asthma and COPD appear to have increased their adherence to inhaler drugs during the Covid-19 era, according to a paper published by the Journal of Allergy and Clinical Immunology. Also, the number of inhalers prescribed by general practitioners in England rose in 2020 by 63% between February 2020 and March 2020, according to the National Health Service (NHS). Also, there are shortages of albuterol inhalers in certain areas of the world, such as the United Kingdom and the United States, because hospitals use them mostly for patients with COVID-19. Thus, during the projected era, Covid-19 increased the growth and prospects for COPD and asthma product manufacturers.

 

Global Devices for Inhaled Medications Market: By Device

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Dry Powder Inhalers, Metered-Dose Inhalers, Nebulizers, and Soft Mist Inhaler. The meter dose inhaler segment held the major market share in 2019, owing to the factors such as inhalation route is the fastest and most effective method of delivering medications to the respiratory system during treatment of COPD and asthma.

 

 

Global Devices for Inhaled Medications Market: By Type

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Preventive Inhaler, Reliever inhaler, Long-acting bronchodilators inhaler. Bronchodilators are drugs that relax the bands of the muscles that tighten around your airways. This opens the airway and lets your lungs move more air in and out of it. That allows you to breathe easier. Bronchodilators also help the lungs expel mucus. Open airways mean that mucus can also flow more easily and can be coughed up.

 

Global Devices for Inhaled Medications Market: By End-use

 

Among these during the forecast period, the home care segment is projected to report the highest growth rate due to the growing geriatric population, increasing per capita expenditure, and increasing knowledge of respiratory diseases. A Healthcare First organization report found that more than 3.4 million people in the U.S. are receiving qualified home health care services from Medicare because of the growing elderly population and the rising prevalence of chronic health problems in the country.

 

Global Devices for Inhaled Medications Market: By Application

 

Based on segmentation, the global Devices for Inhaled Medications market is categorized into Asthma and Chronic Obstructive Pulmonary Disease. Growing geriatric populations with chronic respiratory problems; and lifestyle changes. Also, the launch by pharmaceutical and biotechnology companies of new and innovative pulmonary devices in personalized shapes and sizes, the availability of auto-injectors, and the increase in research and development activities to develop novel oral and nasal drug formulations are some of the other significant factors that are likely to drive the market.

 

Source: BlueWeave Consulting

 

Global Devices for Inhaled Medications Market: Regional insights

The global Devices for Inhaled Medications market is segmented into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the major share of the market size of COPD and asthma devices in 2019 and this trend is expected to continue due to the widespread and early adoption of inhalers & nebulizers and large pools of respiratory disease patients. In addition, the Asia-Pacific region is expected to grow rapidly due to increased spending on healthcare, increased awareness of advanced portable COPD & asthma devices.

Source: BlueWeave Consulting

Recent Development

On July 7, 2020 - Novartis announced that Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) has been approved by the European Commission (EC) as a maintenance treatment for asthma in adult patients not sufficiently managed by a long-acting beta2-a gonist (LABA) and high-dose inhaled corticosteroid (ICS) maintenance combination who have encountered one or more inhaled corticosteroids. The first LABA/Long-acting Muscarinic Antagonist (LAMA)/ICS fixed-dose combination available in the EU for these patients is Enerzair Breezhaler once a day.

On Aug 2017 - Propeller Health, a leading digital respiratory medicine solution, today announced the extension of its partnership with GSK in 2015, allowing both companies to plan for and conduct commercial activities using the clip-on sensor and software platform from Propeller for use with the ELLIPTA Inhaler from GSK. Continuing research and development activities will continue to gather data from the Propeller clip-on sensor and software interface used in combination with GSK's asthma and COPD respiratory medicines.

 

Competitive landscape

Key players for Devices for Inhaled Medications market includes3M Company, Agilent technologies, Aradigm corporation, Astrazeneca plc, Bespak, Beximo pharmaceuticals ltd., Boehringer ingelheimgmbh, Cipla inc., Drive devilbiss healthcare, GE healthcare, Glaxosmithkline, H&T presspart manufacturing ltd, Hovione, Mannkind corporation, Manta devices llc, Midascare, Novartis ag, Omega life sciences, Omron healthcare europeb.v, Philips n.v, Propeller health, Pulmatrix, inc, Savara inc, Spyryx biosciences inc, Teicos pharma ltd, Teijin limited, Teva respiratory llc, Vitalograph, and Other Players.

 

Scope of the Report

 

Attribute Details
Years Considered Historical data – 2015-2019
Base Year – 2019
Forecast – 2020 – 2026
Facts Covered Revenue in USD Million
Market Coverage China, Japan, South Korea, India, ASEAN, US, Canada, Germany, France, UK, Italy, Brazil, Mexico, Saudi Arabia, UAE & South Africa
Product/Service Segmentation By Device, By type, application End User and region
Key Players Key players for global Devices for Inhaled Medicationsmarket are3M Company, Agilent technologies, Aradigm corporation, Astrazeneca plc, Bespak, Beximo pharmaceuticals ltd., Boehringer ingelheimgmbh, Cipla inc., Drive devilbiss healthcare, GE healthcare, Glaxosmithkline, H&T presspart manufacturing ltd, Hovione, Mannkind corporation, Manta devices llc, Midascare, Novartis ag, Omega life sciences, Omron healthcare europeb.v, Philips n.v, Propeller health, Pulmatrix, inc, Savara inc, Spyryx biosciences inc, Teicos pharma ltd, Teijin limited, Teva respiratory llc, Vitalograph, and Other Players

 

By Type

  • Preventive Inhaler
  • Reliever inhaler
  • Long acting bronchodilators inhaler

By Device

  • Dry Powder Inhalers
  • Metered-Dose Inhalers
  • Nebulizers
  • Soft Mist Inhaler

By Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease

By End Use

  • Clinic
  • Hospital
  • Home

By Region:

  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America

 

1.    Research Framework

1.1.     Research Objective

1.2.     Product Overview

1.3.     Market Segmentation

2.    Research Methodology

 

2.1.     Qualitative Research

2.1.1.   Primary & Secondary Applications

2.2.     Quantitative Research

2.3.     Market Breakdown & Data Triangulation

2.3.1.   Primary & Secondary Applications

2.3.2.   Secondary Research

2.3.3.   Primary Research

2.4.     Breakdown of Primary Research Respondents, By Region

2.5.     Assumption & Limitation

3.    Executive Summary

4.    Global Devices for Inhaled Medications Industry Insights

4.1.     Industry Value Chain Analysis

4.2.     DROC Analysis

4.2.1.   Growth Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.2.4.   Challenges

4.3.     Technological Landscape/Recent Development

4.4.     Regulatory Framework

4.5.     Company market share analysis,2018

4.6.     Porter’s Five forces analysis

4.6.1.   Bargaining Power of Suppliers

4.6.2.   Bargaining Power of Buyers

4.6.3.   Threat of New Entrants

4.6.4.   Threat of Substitutes

4.6.5.   Intensity of Rivalry

5.    Global Devices for Inhaled Medications Market Overview

5.1.     Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Million)

5.2.     Market Share & Forecast 2016-2026

5.2.1.   By Device

5.2.1.1.       Dry Powder Inhalers

5.2.1.2.       Metered-Dose Inhalers

5.2.1.3.       Nebulizers

5.2.1.4.       Soft Mist Inhaler

5.2.2.   By Type

5.2.2.1.       Preventive Inhaler

5.2.2.2.       Reliever inhaler

5.2.2.3.       Long acting bronchodilators inhaler

5.2.3.   By Application

5.2.3.1.       Asthma

5.2.3.2.       Chronic Obstructive Pulmonary Disease

5.2.4.   By End User

5.2.4.1.       Clinic

5.2.4.2.       Hospital

5.2.4.3.       Home

5.2.5.   By Region

5.2.5.1.   North America

5.2.5.2.   Europe

5.2.5.3.   Asia Pacific

5.2.5.4.   Latin America

5.2.5.5.   Middle East & Africa

6.    North America Devices for Inhaled Medications Market

6.1.     Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Million)

6.2.     Market Share & Forecast 2016-2026

6.2.1.   By Device

6.2.2.   By Type

6.2.3.   By Application

6.2.4.   By End User

6.2.5.   By Country

6.2.5.1.         U.S

6.2.5.2.         Canada

7.    Europe Devices for Inhaled Medications Market

7.1.     Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Million)

7.2.     Market Share & Forecast 2016-2026

7.2.1.   By Device

7.2.2.   By Type

7.2.3.   By Application

7.2.4.   By End User

7.2.5.   By Country

7.2.5.1.     Germany

7.2.5.2.     U.K

7.2.5.3.     France

7.2.5.4.     Italy

7.2.5.5.     Rest of Europe

8.    Asia Pacific Devices for Inhaled Medications Market

8.1.     Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Million)

8.2.     Market Share & Forecast 2016-2026

8.2.1.   By Device

8.2.2.   By Type

8.2.3.   By Application

8.2.4.   By End User

8.2.5.   By Country

8.2.5.1.     China

8.2.5.2.     India

8.2.5.3.     Japan

8.2.5.4.     Rest of Asia Pacific

9.    Latin America Devices for Inhaled Medications Market

9.1.     Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Million)

9.2.     Market Share & Forecast 2016-2026

9.2.1.   By Device

9.2.2.   By Type

9.2.3.   By Application

9.2.4.   By End User

9.2.5.   By Country

9.2.5.1.     Brazil

9.2.5.2.     Argentina

9.2.5.3.     Rest of Latin America

10. Middle East & Africa Devices for Inhaled MedicationsMarket

10.1. Market Size & Forecast by Value, 2016-2026

10.1.1. By Value (USD Million)

10.2. Market Share & Forecast 2016-2026

10.2.1. By Device

10.2.2. By Type

10.2.3. By Application

10.2.4. By End User

10.2.5.   By Country

10.2.5.1.      Saudi Arabia

10.2.5.2.      UAE

10.2.5.3.      South Africa

10.2.5.4.      Rest of Middle East & Africa

11. Competitive Landscape

11.1. List of Players’ and Their Offerings

11.2. Company Market Ranking/Share Analysis, 2019

11.3. Competitive Benchmarking, By Operating Parameters

12. Impact of COVID-19 across Industry

13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

13.1. 3M Company

13.2. Agilent technologies

13.3. Aradigm corporation

13.4. Astrazeneca plc

13.5. Bespak

13.6. Beximo pharmaceuticals ltd.

13.7. Boehringer ingelheimgmbh

13.8. Cipla Inc.

13.9. Drive devilbiss healthcare

13.10.                GE healthcare

13.11.                Glaxosmithkline

13.12.                H&T presspart manufacturing ltd

13.13.                Hovione

13.14.                Mannkind corporation

13.15.                Manta devices llc

13.16.                Midascare

13.17.                Novartis ag

13.18.                Omega life sciences

13.19.                Omron healthcare europeb.v

13.20.                Philips n.v

13.21.                Propeller health

13.22.                Pulmatrix, inc

13.23.                Savara inc

13.24.                Spyryx biosciences inc

13.25.                Teicos pharma ltd

13.26.                Teijin limited

13.27.                Teva respiratory llc

13.28.                Vitalograph

13.29.                Other Prominent Player

 

List of Figures

Fig: Global Devices for Inhaled Medications Segmentation

Fig: Global Devices for Inhaled Medications Market Value Chain Analysis

Fig: Company Market Share Analysis, 2019

Fig: Global Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: Global Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: Global Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: Global Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: Global Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: Global Devices for Inhaled Medications Market Share, By Region, By Value, 2016-2026

Fig: North America Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: North America Devices for Inhaled Medications Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: North America Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: North America Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: North America Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: North America Devices for Inhaled Medications Market Share, By Country, By Value, 2016-2026

Fig: Europe Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: Europe Devices for Inhaled Medications Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: Europe Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: Europe Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: Europe Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: Europe Devices for Inhaled Medications Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: Asia-Pacific Devices for Inhaled Medications Market Share, By Country, By Value, 2016-2026

Fig: Latin America Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: Latin America Devices for Inhaled Medications Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: Latin-America Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: Latin America Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: Latin America Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: Latin America Devices for Inhaled Medications Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Size, By Value (USD Million), 2016-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Share, By Device, By Value, 2016-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Share, By Type, By Value, 2016-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Share, By Application, By Value, 2016-2026

Fig: Middle-East & Africa Devices for Inhaled Medications Market Share, By End use, By Value, 2016-2026

Fig: Middle East & Africa Devices for Inhaled Medications Market Share, By Country, By Value, 2016-2026

 

List of Tables:

 

Table: Global Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: Global Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: Global Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Global Devices for Inhaled Medications Market Size, By Region, By Value, 2016-2026

Table: North America Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: North America Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: North America Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: North America Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: North America Devices for Inhaled Medications Market Size, By Country, By Value, 2016-2026

Table: Europe Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: Europe Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: Europe Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Europe Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Europe Devices for Inhaled Medications Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: Asia-Pacific Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: Asia-Pacific Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Asia-Pacific Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Asia-Pacific Devices for Inhaled Medications Market Size, By Country, By Value, 2016-2026

Table: Latin America Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: Latin America Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: Latin America Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Latin America Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Latin America Devices for Inhaled Medications Market Size, By Country, By Value, 2016-2026

Table: Middle-East & Africa Devices for Inhaled Medications Market Size, By Device, By Value, 2016-2026

Table: Middle-East Devices for Inhaled Medications Market Size, By Type, By Value, 2016-2026

Table: Middle-East & Africa Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Middle-East & Africa Devices for Inhaled Medications Market Size, By Application, By Value, 2016-2026

Table: Middle East & Africa Devices for Inhaled Medications Market Size, By Country, By Value, 2016-2026

Table: Samsonite. Financial Analysis

Table: Bluesmart Black Edition Financial Analysis

Table: Horizn Studios GmbH Financial Analysis

Table: TraxPack LLC Financial Analysis

Table: Modobag Financial Analysis

Table: Delsey S.A. Financial Analysis

Table: Planet Traveler USA Financial Analysis

Table: Away Com INC Financial Analysis

Table: Néit Products Ltd Financial Analysis

Table: Trunkster Financial Analysis

 

 

 

*Financial Details Not Be Captured in Case of Unlisted Companies

 

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

Market Segmentation

By Type

  • Preventive Inhaler
  • Reliever inhaler
  • Long acting bronchodilators inhaler

By Device

  • Dry Powder Inhalers
  • Metered-Dose Inhalers
  • Nebulizers
  • Soft Mist Inhaler

By Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease

By End Use

  • Clinic
  • Hospital
  • Home

By Region:

  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.